9 recruiting, 4 active not recruiting, 2 completed, 2 not yet recruiting. 18 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Recruiting 9, Active not recruiting 4, Completed 2, Not yet recruiting 2, Terminated 1 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Terminated 1 |
Follow mFOLFIRINOX: new trials by email Literature Review of mFOLFIRINOX trials Research Report on mFOLFIRINOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation RO7836748, Pembrolizumab, mFOLFIRINOX - Solid Tumors | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 540 | 2026-12-31 | 2026-10-30 |
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Genentech, Inc. | 388 | 2026-11-30 | 2026-11-10 |
| A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer ELI-002 7P, Tislelizumab, mFOLFIRINOX - Pancreatic Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2026-06-22 | 2026-10-28 |
| M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors M0324, Pembrolizumab, mFOLFIRINOX - Advanced Solid Tumor | Phase 1 | Recruiting | EMD Serono Research & Development Institute, Inc. | 77 | 2025-10-10 | 2026-11-02 |
| A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer zolbetuximab, mFOLFIRINOX - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Active not recruiting | Astellas Pharma Global Development, Inc. | 12 | 2025-09-24 | 2026-10-16 |
| MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma Zunsemetinib, mFOLFIRINOX - Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 1 | Recruiting | Washington University School of Medicine | 51 | 2025-06-13 | 2026-04-30 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 665 | 2025-03-31 | 2026-06-02 |
| A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB186748, Cetuximab, GEMNabP - Solid Tumors | Phase 1 | Active not recruiting | Incyte Corporation | 30 | 2025-03-27 | 2026-08-25 |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations ALTA3263, cetuximab, mFOLFOX6 - Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Alterome Therapeutics, Inc. | 448 | 2025-03-05 | 2026-10-26 |
| Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer Bortezomib Injection, Sintilimab, mFOLFIRINOX - Pancreas Cancer | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 63 | 2024-11-15 | 2025-01-10 |
| Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma BNT321 0.5 mg/kg, BNT321 DL 2, mFOLFIRINOX - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 1 | 2024-03-27 | 2025-10-31 |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734, Cetuximab, Retifanlimab - Solid Tumors | Phase 1 | Recruiting | Incyte Corporation | 710 | 2024-01-04 | 2026-07-22 |
| Preoperative Radiotherapy And ASTX660 in Rectum Cancer mFOLFIRINOX, Pelvic radiotherapy LCRT, Capecitabine - Locally-advanced Rectal Cancer | Phase 1 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 78 | 2023-12-19 | 2024-02-08 |
| Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Ivosidenib, mFOLFIRINOX - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer | Phase 1 | Active not recruiting | Case Comprehensive Cancer Center | 16 | 2022-09-08 | 2025-09-05 |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer Fluzoparib, Fluzoparib placebo, mFOLFIRINOX - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 39 | 2020-01-21 | 2024-08-16 |
| Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery Atezolizumab, RO7198457, mFOLFIRINOX - Pancreatic Cancer | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 29 | 2019-12-13 | 2026-01-07 |
| Study of Proton Therapy in Adjuvant Pancreatic Cancer mFOLFIRINOX, Proton beam radiation - Resected Pancreatic Adenocarcinoma | Phase 1 | Completed | Georgetown University | 9 | 2019-07-15 | 2024-10-24 |
Pancreatic Neoplasms (6) · Colorectal Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Carcinoma (1) · Colonic Neoplasms (1) · Medullary cystic kidney disease 1 (1) · Neoplasms (1) · Neoplasms by Site (1)
Incyte Corporation (2) · Memorial Sloan Kettering Cancer Center (2) · Alterome Therapeutics, Inc. (1) · Astellas Pharma Global Development, Inc. (1) · BioNTech SE (1) · Case Comprehensive Cancer Center (1) · EMD Serono Research & Development Institute, Inc. (1) · First Affiliated Hospital of Zhejiang University (1) · Genentech, Inc. (1) · Georgetown University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hoffmann-La Roche (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Tango Therapeutics, Inc. (1) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1)
United States (13) · Australia (2) · Canada (2) · China (2) · France (2) · Japan (2) · Belgium (1) · Italy (1) · Spain (1)
Benjamin Weinberg, MD (1) · David Bajor, MD (1) · Kevin Soares, MD (1) · Maxim Pimpkin, MD, PhD (1) · Moh'd Khushman, M.D. (1) · Tingbo Liang (1) · Vinod Balachandran, MD (1) · Xianjun Yu, M.D. (1)
PMID 37034685, PMID 37717786, PMID 39232761, PMID 41790032
2023 (2), P50CA272213 (1)